XBIO — Xenetic Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534525 ·
Last close
$3.07
Market Cap
$7.02M
52W High
$3.68
52W Low
$2.20
ADV30
13,836
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 806,923 | — | -502,117 | -456,382 | 7,908,991 | 7,347,255 | 958,239 |
| Dec 2025 | 766,296 | — | -623,027 | -579,076 | 8,363,847 | 7,883,632 | 968,025 |
| Sep 2025 | 1,026,957 | — | -544,734 | -509,940 | 5,067,960 | 4,121,599 | 1,111,775 |
| Jun 2025 | 589,897 | — | -724,412 | -688,703 | 5,353,700 | 4,779,846 | 903,430 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,286,651
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.65
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-199,875,331
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-2,834,582
Pretax Income TTM
$-2,680,860
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,190,073
EBITDA
—
Free Cash Flow
$-1,075,527
Enterprise Value
$-406,192
Total Cash
$7,347,255
Total Debt
$0
Shares Out
2,291,056
Trailing EPS
$-1.19
Book Value
$3.23
ROE
-37.0%
ROA
-21.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,976,411 | -2,834,582 | -2,680,860 | 8,363,847 | 968,025 | — | -2,286,651 |
| Dec 2024 | 2,500,284 | -4,204,428 | -3,960,275 | 6,901,443 | 894,263 | — | -2,817,478 |
| Dec 2023 | 2,539,986 | -4,515,715 | -4,134,578 | 10,605,226 | 809,585 | — | -4,114,219 |
| Dec 2022 | 1,706,925 | -6,717,908 | -6,552,353 | 14,720,290 | 1,073,156 | — | -4,646,765 |
TTM Snapshot
Revenues TTM
$35,967
NetIncome TTM
$-29,264
OpCashFlow TTM
$0
Assets (Latest)
$222,500
Forward EPS
$-0.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SYBX | SYNLOGIC, INC. | $7.02M | $0.60 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $6.88M | $2.50 | — |
| SBFM | Sunshine Biopharma Inc. | $6.73M | $0.42 | — |
| CANF | Can-Fite BioPharma Ltd. | $7.37M | $3.44 | — |
| SILO | Silo Pharma, Inc. | $6.69M | $0.41 | — |
News headlines (Yahoo Finance, 1h cache)
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
2026-05-13 12:05 · Yahoo
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
2026-04-22 13:00 · Yahoo
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
2026-03-13 12:00 · Yahoo
Xenetic Biosciences: Q4 Earnings Snapshot
2026-03-12 22:32 · Yahoo
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
2025-12-11 22:00 · Yahoo
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
2025-11-19 13:45 · Yahoo
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
2025-11-13 13:45 · Yahoo
Xenetic Biosciences: Q3 Earnings Snapshot
2025-11-12 22:43 · Yahoo
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
2025-10-30 11:15 · Yahoo
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
2025-10-10 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.